Does Horizon Blue Cross Blue Shield of New Jersey Cover Forteo?

What Is Forteo and Why Does Coverage Get Complicated?

Forteo is a brand-name injectable parathyroid hormone analog (teriparatide 20 mcg/day) approved by the FDA in 2002 for the treatment of osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and women or men with glucocorticoid-induced osteoporosis at high fracture risk [1]. It works by stimulating bone formation rather than simply slowing resorption, which distinguishes it mechanically from bisphosphonates and denosumab.

Coverage gets complicated because Forteo sits in the specialty drug category on nearly every commercial formulary. Specialty drugs often require insurer approval before the pharmacy will dispense them, and Horizon BCBS NJ is no exception.

Why Specialty Tier Classification Matters

Specialty drug tiers carry the highest cost-sharing. On a typical Horizon tiered formulary, a Tier 4 specialty drug can require 20 to 30 percent coinsurance after deductible, which translates to hundreds of dollars per month for a drug whose list price exceeds $3,000 per month. The FDA label also imposes a 24-month lifetime limit, making the cost-per-treatment-course conversation essential before starting therapy [1].

Biosimilars and Generics Changing the Field

The entry of lower-cost teriparatide products has shifted insurer formulary decisions. Teriparatide-tjlv (brand name Bonsity) received FDA approval in 2021 [2], and Tymlos (abaloparatide), a related but distinct anabolic agent, is FDA-approved and often placed on a lower formulary tier than brand Forteo. Horizon plans may prefer one of these alternatives, which affects how the prior authorization criteria are written for brand Forteo specifically.

How Horizon BCBS NJ Prior Authorization Works for Forteo

Prior authorization (PA) is a formal insurer review confirming medical necessity before coverage is granted. For Forteo, Horizon's PA criteria are aligned closely with national clinical guidelines from the American Association of Clinical Endocrinologists (AACE) and the National Osteoporosis Foundation (NOF).

Standard Clinical Criteria Horizon Uses

Most Horizon commercial plans require all of the following to approve Forteo:

1. A diagnosis of osteoporosis confirmed by dual-energy X-ray absorptiometry (DXA) showing a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip [3].
2. High or very high fracture risk. The AACE 2020 clinical practice guidelines define very high risk as T-score <-3.0 with prior fracture, or T-score <-3.5 regardless of fracture history [4].
3. Documentation of an inadequate response to, or intolerance of, at least one oral bisphosphonate. Alendronate 70 mg weekly is the most commonly specified agent and the step-therapy threshold is generally 6 to 12 months of documented use.
4. Prescriber must be a physician licensed to treat osteoporosis, typically an endocrinologist, rheumatologist, or gynecologist.

The AACE/ACE 2020 guidelines state: "Anabolic therapy should be considered for patients at very high risk of fracture, especially those with multiple vertebral fractures or very low bone mineral density" [4]. Horizon's PA criteria reflect this hierarchy.

Step Therapy: The Bisphosphonate Requirement

Step therapy means you must try a less expensive medication first. For Forteo, that almost always means alendronate (Fosamax) or risedronate (Actonel), both of which are generic and inexpensive. Horizon typically requires at least a 6-month trial with documented compliance, followed by either:

• A new low-trauma fracture occurring during therapy, or
• A decline in bone mineral density of more than 5 percent at the spine or hip, or
• A documented clinical contraindication or significant adverse effect such as osteonecrosis of the jaw, atypical femur fracture, or severe esophageal disease.

Patients with glucocorticoid-induced osteoporosis may qualify for an expedited pathway because the American College of Rheumatology 2022 guidelines recommend anabolic therapy earlier in high-risk glucocorticoid users [5].

How to Submit the PA

The prescribing physician's office submits the PA through Horizon's NaviNet portal or via fax using the specialty drug prior authorization form. Required documents include:

• DXA report with T-scores
• FRAX score or equivalent fracture risk assessment
• 12-month prescription history for prior bisphosphonate
• Office notes documenting fracture history, fall risk, or contraindications
• Diagnosis codes (M81.0 for age-related osteoporosis with pathological fracture, M81.6 for localized osteoporosis, Z82.61 for family history)

Horizon is required under New Jersey state law to respond to standard PA requests within 3 business days and urgent requests within 24 hours [6].

Forteo on Horizon Medicare Advantage Plans

Horizon offers Medicare Advantage (MA) products in New Jersey, including Horizon Medicare Blue and Horizon Medicare Advantage. Coverage rules under MA differ from commercial plans because they follow CMS Part D regulations.

Part D Formulary Placement

Under Part D, teriparatide products are typically placed in Tier 5 (specialty). The standard Part D out-of-pocket catastrophic cap was restructured by the Inflation Reduction Act of 2022, meaning Part D enrollees now face a $2,000 annual out-of-pocket cap starting January 1, 2025 [7]. For a drug as expensive as Forteo, many MA members will reach this cap relatively early in the plan year, substantially reducing their total annual cost.

Coverage Determination vs. Prior Authorization

Under Medicare Part D, Horizon must follow CMS coverage determination rules. A standard coverage determination takes 72 hours; an expedited determination requires a response within 24 hours when a standard decision could seriously jeopardize health [8]. If denied, members have the right to appeal through a structured process: redetermination by Horizon, reconsideration by a Qualified Independent Contractor (QIC), ALJ hearing, Medicare Appeals Council review, and federal district court.

What Forteo Costs With and Without Horizon Coverage

List price for Forteo runs approximately $3,200 to $3,500 per month as of mid-2025. Generic teriparatide (Bonsity) lists around $1,800 per month. The actual member cost depends on the plan's formulary tier, deductible status, and coinsurance structure.

Typical Cost-Sharing Scenarios

A member in the deductible phase (before meeting the annual deductible) may pay the full allowed cost. After the deductible, Horizon commercial plans often apply:

• Tier 3 specialty: 20 percent coinsurance, typically $200 to $500 per month depending on the allowed amount
• Tier 4 specialty: 30 percent coinsurance, typically $500 to $900 per month

These are illustrative ranges. Actual cost-sharing must be confirmed in the specific plan's Summary of Benefits and Coverage (SBC) or by calling the member services number on the insurance card.

Manufacturer Savings and Patient Assistance

Eli Lilly, which manufactures Forteo, offers a savings card for commercially insured patients that may reduce monthly cost to $0 for eligible patients. Income-based patient assistance is available through the Lilly Cares Foundation for uninsured or underinsured patients [9]. Members who are denied coverage or face unaffordable cost-sharing should ask the prescribing physician's office to contact Lilly's reimbursement support line directly.

Bonsity's manufacturer, Alvogen, also offers patient assistance for lower-income patients [2]. If Horizon requires the generic teriparatide, confirming whether the savings program applies to that product is a necessary first step.

The Appeals Process When Horizon Denies Forteo

Denial is not the end of the road. New Jersey's Health Care Quality Act and federal regulations give members structured appeal rights, and anabolic osteoporosis therapy denials are frequently overturned when the clinical record is complete.

Internal Appeal

An internal appeal must be filed within 180 days of receiving the denial notice on commercial plans. Horizon reviews the appeal with a physician not involved in the original decision. The appeal should include:

• A letter of medical necessity from the prescribing physician citing specific AACE, NOF, or ACR guidelines
• DXA reports showing trend in bone mineral density
• Fracture history and radiology reports
• Documentation of bisphosphonate failure or intolerance

The AACE 2020 guidelines explicitly state that anabolic agents are first-line for very high-risk patients, and citing that language in the appeal letter strengthens the clinical argument [4].

External Appeal

If the internal appeal is denied, New Jersey members can request an external appeal reviewed by an independent organization certified by the state. Under the New Jersey Independent Health Care Appeals Program (IHCAP), external reviewers are board-certified specialists with no financial relationship to Horizon [6]. External appeal decisions are binding on the insurer.

Expedited Appeals for Urgent Cases

When a member has already started Forteo and is facing a coverage interruption, or when a delay in treatment could cause irreversible harm (for example, a patient with multiple vertebral compression fractures), the expedited appeal pathway compresses the timeline to 72 hours for internal review.

Clinical Evidence Supporting Forteo Coverage Decisions

Horizon's medical policy criteria track the published clinical evidence. Understanding the trial data helps physicians write stronger PA letters and helps members understand why the criteria exist.

Fracture Risk Reduction

The key teriparatide trial (Neer et al., 2001, N=1,637 postmenopausal women) demonstrated that teriparatide 20 mcg/day reduced new vertebral fractures by 65 percent compared to placebo (relative risk 0.35, 95% CI 0.22 to 0.55, P<0.001) and reduced new nonvertebral fragility fractures by 53 percent [10]. This trial remains the cornerstone of FDA approval and insurer medical policy.

Comparison with Antiresorptive Therapy

The DATA (Denosumab And Teriparatide Administration) trial demonstrated superior gains in bone mineral density at the lumbar spine with combination denosumab plus teriparatide versus either agent alone at 12 months [11]. This finding supports the clinical rationale for anabolic therapy in patients who have failed antiresorptive monotherapy, which is precisely what step therapy is designed to assess.

Glucocorticoid-Induced Osteoporosis Evidence

In a 36-month randomized controlled trial (Saag et al., 2007, N=428), teriparatide produced significantly greater increases in lumbar spine BMD compared to alendronate in patients receiving long-term glucocorticoid therapy [12]. This evidence supports earlier use of anabolic therapy in glucocorticoid-exposed patients, and the American College of Rheumatology 2022 guidelines reflect this by recommending teriparatide or abaloparatide for high-risk glucocorticoid-induced osteoporosis patients [5].

Sequential Therapy Considerations

Clinical guidelines recommend following anabolic therapy with antiresorptive consolidation to preserve gained bone mass. The AACE 2020 guidelines specify that after completing a course of teriparatide or abaloparatide, patients should transition to denosumab or a bisphosphonate [4]. Horizon's PA process may ask for a transition plan when approving the full 24-month course, and documenting that plan at the outset streamlines the process.

How Generic Teriparatide Affects Your Coverage

The availability of teriparatide biosimilars and follow-on biologics has created new formulary dynamics. Horizon may prefer Bonsity (teriparatide-tjlv) over brand Forteo because the acquisition cost is lower, even though the two products are therapeutically equivalent.

Generic Substitution and Therapeutic Interchange

New Jersey law allows pharmacists to substitute an interchangeable biological product without prescriber authorization, but teriparatide-tjlv's interchangeability designation status should be confirmed at the time of dispensing. If Horizon's formulary requires Bonsity and the prescriber has written for Forteo, the PA denial may cite non-preferred brand as the reason. In that case, the physician can either:

1. Accept the substitution to Bonsity, which is clinically equivalent, or
2. Submit a medical exception request demonstrating a specific clinical reason the member requires brand Forteo (for example, a documented sensitivity to an excipient in Bonsity).

The FDA's guidance on interchangeable biological products is clear that substitution should not change clinical outcomes for the majority of patients [13].

FRAX Score and Coverage Probability

A higher FRAX 10-year major osteoporotic fracture probability correlates with stronger PA approval rates. The NOF recommends pharmacologic treatment when the FRAX probability exceeds 20 percent for major osteoporotic fracture or 3 percent for hip fracture [3]. Horizon's criteria align with these thresholds, and including the FRAX calculation in the PA submission reduces back-and-forth with the insurer.

Practical Steps to Maximize Approval Chances

Getting a Forteo PA approved requires preparation. Physicians and patients who approach the process systematically see higher first-round approval rates.

Pre-Submission Checklist

Before submitting the PA, confirm that the chart documents all of the following:

• A DXA scan performed within the past 24 months with a T-score <-2.5 at the spine, hip, or femoral neck [3]
• FRAX score above the NOF treatment threshold [3]
• At least 6 months of bisphosphonate therapy with adherence documentation (prescription fill history), unless a contraindication is documented
• The specific reason bisphosphonate therapy was inadequate (fracture on therapy, BMD decline, intolerance)
• A treatment plan that includes post-teriparatide antiresorptive consolidation
• Specialist involvement if required by the plan

Real-World Approval Rates

A 2022 analysis of specialty drug PA submissions published in JAMA Internal Medicine found that 18.1 percent of initial PA requests across commercial insurers were denied, but that 39 percent of appeals were overturned [14]. For anabolic osteoporosis drugs specifically, denial rates tend to be higher at initial submission because bisphosphonate step-therapy documentation is often incomplete, not because the clinical need is absent.

Coordinating with the Specialty Pharmacy

Horizon typically requires Forteo to be dispensed through a contracted specialty pharmacy. The prescribing office should verify which specialty pharmacy is in-network for the member's plan before submitting the PA, because a PA approved for one dispensing entity may not transfer automatically to another. Accredo and Optum Specialty Pharmacy are common Horizon-contracted specialty pharmacies, but the member's current benefits should be confirmed at the time of prescribing.

Horizon Medicaid (NJ FamilyCare) and Forteo

Horizon also administers NJ FamilyCare (New Jersey's Medicaid managed care) plans. Coverage rules for Forteo under Medicaid differ significantly from commercial plans.

Medicaid Preferred Drug List

New Jersey's Medicaid program maintains a Preferred Drug List (PDL). Generic teriparatide and oral bisphosphonates are more likely to be preferred. Brand Forteo may require a PA under Medicaid that is separate from and more stringent than commercial criteria. Prescribers should consult the current New Jersey Medicaid PDL for updated formulary status [15].

Income-Based Cost-Sharing

Medicaid members have minimal cost-sharing for covered drugs. If teriparatide is covered under NJ FamilyCare, the member copay is typically $1 to $3 per prescription. The primary barrier is PA approval, not cost-sharing.

A Note on Monitoring Requirements During Forteo Therapy

Insurers, including Horizon, sometimes require documentation of monitoring compliance as a condition of continued authorization. The FDA label for Forteo recommends baseline and periodic assessment of serum calcium and monitoring for hypercalcemia, particularly in patients with pre-existing conditions that predispose to elevated calcium [1]. The Endocrine Society's clinical practice guideline on osteoporosis also recommends repeat DXA at 1 to 2 years to assess treatment response [16].

Keeping these monitoring visits documented in the chart and submitting the results with any reauthorization request reduces the likelihood of a coverage gap between the initial 6-month or 12-month authorization and the full 24-month course.

Serum alkaline phosphatase and markers of bone turnover (P1NP, CTx) are not universally required by Horizon but can serve as supporting evidence of anabolic response if the reauthorization is disputed.

The FDA originally included a black box warning about osteosarcoma risk in rodents, though a 15-year postmarketing surveillance study (the CORE study) found no causal association with osteosarcoma in humans [17]. Horizon's PA criteria do not restrict use on the basis of this warning, but documenting that the prescriber has discussed it with the patient is standard practice and may be requested in the PA review.